



(51) International Patent Classification:

C07D 417/14 (2006.01) *A61K 31/496* (2006.01)
C07D 487/04 (2006.01) *A61K 31/4439* (2006.01)
A61P 31/04 (2006.01) *A61K 31/454* (2006.01)
A61K 31/427 (2006.01) *A61K 31/437* (2006.01)

(21) International Application Number:

PCT/US2015/022011

(22) International Filing Date:

23 March 2015 (23.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/969,735 24 March 2014 (24.03.2014) US
 62/088,304 5 December 2014 (05.12.2014) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **AULAKH, Virender Singh** [CA/CA]; 95 B Keewenaw Drive, Whitehorse, Yukon Y1A 0B5 (CA). **CASAREZ, Anthony** [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **LIN, Xiaodong** [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **LINDVALL, Mika** [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **MCENROE, Glenn** [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **MOSER, Heinz Ernst** [US/US]; Novartis Institutes

for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **RECK, Folkert** [DE/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **TJANDRA, Meiliana** [ID/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **SIMMONS, Robert Lowell** [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **YIFRU, Aregahegn** [CA/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US). **ZHU, Qingming** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608-2916 (US).


(74) Agent: **SMITH, Michael G**; Novartis Pharmaceuticals Corporation, IP Services Mail Data, One Health Plaza 101/2, East Hanover, New Jersey 07936 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

[Continued on next page]

(54) Title: MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS



(I)

(57) Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.



DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*